Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Brain Neoplasms
Open-data reference.
15 US clinical trials · 8 currently recruiting
Active & Recent Trials
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Jasper Gerritsen
NCT06118723
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Erasmus Medical Center
NCT06273176
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
Dartmouth-Hitchcock Medical Center
NCT06930846
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
NCT05538130
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Stemline Therapeutics
NCT05386108
Guided Meditation During Radiation Therapy for Brain Tumors
University of Utah
NCT06165653
Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors
Mayo Clinic
NCT06322602
Intraoperative Fluorescence-Guided Aspirate Tissue Monitoring of 5-ALA During Brain Tumor Surgery
University of Illinois at Chicago
NCT07111182
[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
Telix Pharmaceuticals (Innovations) Pty Limited
NCT07238322
An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Bristol-Myers Squibb
NCT02667587
Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
Pharmacyclics
NCT00054795
Hypovitaminosis D in Neurocritical Patients
University of Utah
NCT02881957
Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00075166
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
AbbVie (prior sponsor, Abbott)
NCT00649207
(1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients Who Receive Neurotoxic Therapy
National Cancer Institute (NCI)
NCT00001807
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 3 |
| Phase 2 | 1 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Brain Neoplasms Trial Landscape
ClinicalTrials.gov lists 15 US studies indexed under Brain Neoplasms, and 8 of those are currently open to recruitment — roughly 53% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Brain Neoplasms shows 3 late-stage studies (Phase 3 and Phase 4 combined) alongside 4 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Brain Neoplasms is led by University of Utah with 2 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 15 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Brain Neoplasms?
PlainTrial tracks 15 US clinical trials for Brain Neoplasms, of which 8 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Brain Neoplasms?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.